This Article Abstract Full Text (PDF) All Versions of this Article: 88/7/681    most recent hh0701.088769v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Olivot, J.-M. Articles by Rendu, F. Search for Related Content PubMed PubMed Citation Articles by Olivot, J.-M. Articles by Rendu, F. Related Collections Cell signalling/signal transduction Endothelium/vascular type/nitric oxide

(Circulation Research. 2001;88:681.)
© 2001 American Heart Association, Inc.

Cellular Biology

Thrombomodulin Prolongs Thrombin-Induced Extracellular Signal–Regulated Kinase Phosphorylation and Nuclear Retention in Endothelial Cells

Jean-Marc Olivot, Eva Estebanell, Monique Lafay, Brigitte Brohard, Martine Aiach, Francine Rendu

From the Unité INSERM 428, Faculté de Pharmacie, Université René Descartes, Paris, France. Present address for J.-M.O. is Service de Neurologie, Hôpital Tenon, Paris, France. Present address for E.E. is Servicio de hemoterapia y hemostasia, Hospital Clinic, Barcelona, Spain.

Correspondence to Dr Francine Rendu, U428 INSERM, Faculté de Pharmacie, 4 avenue de l’Observatoire, F-75270, Paris, Cedex, France. E-mail rendu{at}pharmacie.univ-paris5.fr

	Abstract

Top Abstract Introduction Materials and Methods Results Discussion References

 
Abstract—On endothelial cells, thrombin binds to thrombomodulin (TM), an integral membrane-bound glycoprotein, and to protease-activated receptors (PARs). Thrombin binding to TM modulates endothelial cell and smooth muscle cell proliferation mediated through PAR1. We studied the phosphorylation and nuclear translocation of extracellular signal–regulated kinases (ERKs) 1 and 2 in human umbilical vein endothelial cells activated by thrombin. Thrombin and thrombin receptor–activating peptide (TRAP)-induced DNA synthesis were significantly inhibited by PD98059, an inhibitor of ERK phosphorylation. Immunoblots of phosphorylated ERKs (pERKs) and immunocytochemical studies of pERK localization revealed differences in the signal generated by thrombin and TRAP. After a short activation (15 minutes), the phosphorylation and the intracellular localization of pERKs were the same with the 2 agonists. After 4 hours, however, pERKs were visualized in the nuclei of thrombin-activated cells but barely detectable in TRAP-activated cells. Moreover, after 4 hours, the pERKs were visualized in the nuclei of cells stimulated by TRAP in the presence of a thrombin mutant that bound to TM, whereas they were around the nuclei in cells stimulated by thrombin in the presence of a monoclonal antibody preventing thrombin binding to TM. The results demonstrate that ERKs are involved in human umbilical vein endothelial cell DNA synthesis mediated by PAR agonists, that the duration of pERK nuclear retention is in inverse ratio to the mitogenic response, and that in addition to its role in the regulation of blood coagulation, TM acts as a thrombin receptor that modulates the duration of pERK nuclear retention and cell proliferation in response to thrombin.

Key Words: thrombin • thrombomodulin • human endothelial cells • mitogen-activated protein kinase

	Introduction

Top Abstract Introduction Materials and Methods Results Discussion References

 
Thrombin is a multifunctional serine protease generated at sites of vascular injury. Thrombin plays a key role in blood coagulation and thrombotic disorders. It acts as the central enzyme of the coagulation cascade by cleaving fibrinogen into fibrin and favoring its own production by activating several coagulation factors by limited proteolysis. Thrombin also regulates its own formation after binding to thrombomodulin (TM), an integral membrane-bound glycoprotein expressed on endothelial cells. TM acts as a cofactor of thrombin to activate protein C, a serine protease ensuring proteolytic inactivation of 2 coagulation factors, factor Va and factor VIIIa. Thrombin also interacts with a variety of cells mediating inflammatory and proliferative responses to vascular injury.¹ For all protein and cellular interactions, thrombin has a recognition site and a catalytic active site. By the former, called the anion-binding exosite (ABE1), thrombin binds to specific negatively charged sequences. By the catalytic site, thrombin exerts its proteolytic activity.²

On vascular endothelial cells, thrombin ABE1 binds to TM. This binding occurs through the epithelial growth factor (EGF)-like domains 4 and 5 of TM.³ Thrombin ABE1 also binds to the typical heptahelical thrombin receptor, the first member of protease-activated G protein–coupled receptor family (PAR1).⁴ Thrombin catalytic site cleaves the amino-terminal tail of PAR1 that flips over to effect receptor activation. Endothelial cell responses to thrombin include prostacyclin, von Willebrand factor secretion, and cell proliferation.⁵ Synthetic peptides that mimic this new aminoterminus, so-called thrombin receptor–activating peptides (TRAPs), are full agonists for receptor activation, even after thrombin cleavage.⁶

Comparison of thrombin and TRAP as to their ability to induce proliferation has led to the postulation that TM modulates PAR1 activation. Overexpression of TM on smooth muscle cells downregulates proliferation (estimated by ³H thymidine incorporation into the DNA) induced by both TRAP and thrombin, and the degree by which cell proliferation was blocked is directly correlated with the level of TM expressed on the cell surface.⁷ On endothelial cells, the inhibition of thrombin binding to TM by a monoclonal antibody 3E2, directed against the fourth EGF-like domain,⁸ resulted in an increase of thrombin mitogenic effect.⁹ In a wide range of tumoral cells, TM seems to exert an inhibitory effect on cell proliferation¹⁰ independently of its thrombin cofactor activity. Thus, TM not only acts as a cofactor for protein C activation to inhibit thrombin generation but also seems to modulate the mitogenic signal triggered by PAR1 activation.

The mitogenic signal induced by many stimuli occurs through mitogen-activated protein kinases (MAPKs), among which are the two extracellular signal–regulated kinases (ERKs) p44^ERK1 and p42^ERK2. ERK1 and ERK2 are ubiquitous cytosolic serine-threonine kinases involved in cellular growth and proliferation. Their activation requires phosphorylation of their tyrosine and threonine residues.¹¹ Phosphorylation of ERKs promotes their dimerization and nuclear translocation.^{12 13} Once in the nucleus, phosphorylated ERKs (pERKs) activate various transcription factors. Duration of ERK phosphorylation and nuclear translocation are thus determinant for cell responses.¹⁴ In fibroblasts, thrombin and TRAP activate ERKs to induce their proliferation.¹⁵ In endothelial cells, pERKs activate cytosolic phospholipase A₂ implicated in prostacyclin secretion.^{16 17}

With this as background, we studied the TM-modulating role on thrombin-induced nuclear translocation of pERKs. For this purpose, we used an antibody anti-TM to prevent thrombin binding to TM and a thrombin mutant with no catalytic activity but the ability to bind TM. Our study indicates that in human umbilical vein endothelial cells (HUVECs), PAR stimulation leads to ERK phosphorylation and nuclear translocation and TM downregulates PAR signal to enhance pERK nuclear retention.

	Materials and Methods

Top Abstract Introduction Materials and Methods Results Discussion References

 
Materials
Human purified thrombin was purchased from Diagnostica Stago. The synthetic TRAP (SFLLRN) and the anti-TM antibody 3E2 were from Serbio. S195A was provided by Dr B. Le Bonniec¹⁸ (Faculté de Pharmacie, Paris, France). Polyclonal anti-ERK antibodies were purchased from New England Biolabs. PD98059 was from Calbiochem. Peroxidase coupled and biotinylated anti-rabbit antibodies and [³H]-thymidine were purchased from Amersham. All culture medium and material were purchased as previously described.⁹ Texas Red streptavidin was from Jackson ImmunoResearch, Interchim. The nucleus marker 4,6-diamidino-2-phenylindol (DIAP) Vectashield was from Vector Laboratories.

Cell Culture
HUVECs were obtained as originally described by Jaffe et al.¹⁹ Cells were maintained in a humidified atmosphere of 5% CO₂ at 37°C, and the culture medium was changed every 48 hours until cells were confluent. Cells were detached by 0.5% trypsin-EDTA and were seeded either on 6-well plates for immunoblotting studies and mitogenesis assay or on glass coverslips for immunocytochemical studies. Cells were used at first and second passages.

³H-Thymidine Incorporation Into the DNA
The DNA synthesis was evaluated by measuring the incorporation of 5'-[³H]-thymidine in the insoluble material precipitated with trichloroacetic acid, as previously described.⁹ PD98059 was added 15 minutes before agonists.

Immunoblotting
Cells that had reached 80% confluence were serum-starved (0.5% FCS) for 18 hours. The agonists thrombin (10 nmol/L), TRAP (100 µmol/L), and S195A (200 nmol/L) and the 3E2 antibody (50 µg/mL) were added in the culture medium without FCS. At the end of the stimulation, cells were lysed, and proteins were separated by gel electrophoresis. Proteins were transferred on nitrocellulose, and the phosphorylated forms of p44^ERK1 and p42^ERK2 were identified with the anti–phospho-ERK antibody (1:1000 in Tris-buffered saline [TBS]) according to the manufacturer’s instructions (New England Biolabs). The amount of p44^ERK1 and p42^ERK2 proteins within each sample was controlled after stripping of the blot that was reprobed with a polyclonal anti-ERK1 and anti-ERK2 antibody (1:1000 in TBS) to ensure that equivalent amounts of ERKs were present.

Immunocytochemical Analysis
The localization of pERKs was studied as previously described for fibroblasts.²⁰ HUVECs were seeded on gelatin-coated glass coverslips and activated as above. HUVEC activation was stopped by removal of the medium and washed in TBS (Tris 0.2 mol/L and NaCl 0.8 mol/L, pH 7.6). The cells were fixed in 50% vol/vol methanol and 50% vol/vol acetone at 20°C for 8 minutes. After 6 washes in TBS, cells were incubated overnight at 4°C with the anti–phospho- ERK antibody (1:200 in TBS containing 3% vol/vol BSA). The incubation was stopped by 6 washes in TBS, and cells were incubated with biotinylated anti-rabbit IgG for 1 hour. After 6 washes in TBS, cells were incubated with Texas Red streptavidin for 1 hour. After the last washing step, cells were fixed for 30 seconds in absolute ethanol, washed in TBS and covered with mounting medium with DIAP, and examined with excitation-emission filters for rhodamine and for DIAP.

Statistical Analysis
Results of mitogenic assay were compared using Student’s t test. For immunocytochemical analysis, at least 80 to 150 cells from at least 3 separate experiments were examined to quantitate the amount of pERK visualized. Statistical analysis was performed using Student’s unpaired t test.

	Results

Top Abstract Introduction Materials and Methods Results Discussion References

 
Effect of MEK Inhibitor PD98059 on ³H-Thymidine Incorporation Into DNA Induced by TRAP or Thrombin
To establish whether ERKs are involved in HUVEC proliferation induced by thrombin or TRAP, we studied the effect of the MAPK kinase (MEK) inhibitor PD98059.²¹ Cell proliferation was estimated by [³H]-thymidine incorporation.²² As previously shown, HUVEC proliferation is more important in response to TRAP than to thrombin, at optimal concentrations, ie, 10 nmol/L and 100 µmol/L for thrombin and TRAP, respectively (Figure 1).⁹ Increasing concentrations of PD98059 resulted in significant decrease in DNA synthesis induced by thrombin or TRAP. The inhibitory effect of 10 µmol/L PD98059 was >80% both with thrombin and TRAP. This concentration was ascertained to inhibit thrombin- and TRAP-induced ERK phosphorylation but not global tyrosin phosphorylation in HUVECs (data not shown). The results show that DNA synthesis induced by thrombin and TRAP involves the phosphorylation of ERKs in HUVECs.

View larger version (19K): [in this window] [in a new window]   Figure 1. MEK inhibitor, PD98059, inhibits 3H-thymidine incorporation in HUVECs. After addition of 10 nmol/L thrombin or 100 µmol/L TRAP in the presence of 10 µmol/L PD98059 or vehicle, 3H-thymidine incorporation into endothelial cells was measured. Results are presented as median of 3 different experiments±SEM. *Student’s unpaired t test; P<0.05. Inset, Effect of increasing PD98059 concentrations on 3H-thymidine incorporation induced by thrombin (solid lines) or by TRAP (dashed lines).

Kinetics of ERK Phosphorylation Induced by Thrombin and TRAP
The phosphorylation of ERKs was analyzed by Western blotting using an antibody specific for the phosphorylated forms of p44^ERK1 and p42^ERK2. After the addition of TRAP or thrombin, the two proteins were rapidly and heavily phosphorylated after 15 minutes (Figure 2, top). The maximum phosphorylation level was identical with the two agonists and was reached between 60 and 90 minutes (top left). After 3 hours of activation, ERKs were slightly less phosphorylated with TRAP than with thrombin, a difference even more pronounced after 4 and 5 hours (top right). The dephosphorylation of ERKs back to the basal level was complete after 5 hours with TRAP and 6 hours with thrombin (not shown). An immunoblot anti-ERK1 and anti-ERK2 was performed at each time of activation to ensure that equal amounts of total ERKs were deposited on the gel before the blot analysis (Figure 2, bottom).

View larger version (17K): [in this window] [in a new window]   Figure 2. Kinetics of phosphorylation of ERKs after thrombin- and TRAP-induced stimulation of HUVECs. Cells were either unstimulated or stimulated by 10 nmol/L thrombin or 100 µmol/L TRAP for the indicated times. Cells were lysed, and samples were separated on SDS-PAGE. Blots were probed with anti–phospho-ERKs (top). Blots were stripped and reprobed with anti-general ERK antibody (bottom).

ERK Phosphorylation and Localization Triggered by TRAP or Thrombin
Phosphorylation of MAPKs is essential for their activation and nuclear translocation.^{11 13} Moreover, MAPK nuclear retention duration is critical for the determination of the response.¹⁴ We therefore studied the intracellular localization by immunofluorescence (Figure 3). For this purpose, the pERK1 and pERK2 were visualized by Texas Red, and the nucleus was visualized by coloring with blue. Before the addition of the inducers (Figure 3A), pERKs were at basal level and could not be detected at a significant level in the cytoplasm nor in the nucleus. After the addition of TRAP and thrombin, the two proteins were rapidly phosphorylated to the same level with the two agonists after 15 minutes (Figures 3C and 3D) and the pERKs were scattered in both the nucleus and the cytosol, with an important amount in the nucleus. After 4 hours of activation, ERKs were less phosphorylated than at short times and more retained in the nucleus of HUVECs with thrombin (Figure 3F) than with TRAP (Figure 3E). Thus, 27% of thrombin-stimulated cells exhibited high-level pERKs in their nucleus (Figure 3F) compared with 7% in TRAP-stimulated cells (P=0.04). The results suggest that in HUVECs the amount of DNA synthesis generated by PAR1 stimulation is inversely correlated with the duration of nuclear pERK retention.

View larger version (17K): [in this window] [in a new window]   Figure 3. Immunolocalization of pERKs after thrombin- and TRAP-induced stimulation of HUVECs. Cells were either unstimulated (A and B) or stimulated by 100 µmol/L TRAP (C and E) or 10 nmol/L thrombin (D and F). After 15 minutes (C and D) or 4 hours (E and F) of stimulation, cells from duplicate wells were fixed and examined by fluorescence microscopy after staining with the same anti–phospho-ERK antibody, a second biotinylated antibody, and Texas Red streptavidin and after staining with DIAP (blue) to visualize the nucleus. Unstimulated cells were incubated with either saline (A) or an irrelevant antibody (B) and stained as above. Bar=30 µm.

Regulation of the PAR1-Generated Activation Signal by Thrombomodulin
In view of the modulating effect of TM on PAR1 activation that we described on DNA synthesis in HUVECs,⁹ we searched for a modulating effect of TM on ERK phosphorylation duration. For this purpose, we used 2 different tools: S195A, a mutant thrombin that binds to TM and has no proteolytic activity,¹⁸ and a specific anti-TM antibody. Results obtained with the mutant thrombin S195A are presented in Figure 4. The thrombin mutant S195A (200 nmol/L), which does not stimulate DNA synthesis,⁹ induced a low phosphorylation of ERKs (Figure 4B) compared with control (Figure 4A). The addition of S195A simultaneously with TRAP resulted in a higher ERK phosphorylation after 4 hours (Figure 4D) than in the presence of TRAP alone (Figure 4C). Moreover, S195A retained the pERKs in the nucleus (Figure 4D), whereas phospho-ERKs were no longer present after 4 hours of stimulation by TRAP alone (Figure 4C). The number of cells exhibiting a high level of pERK was increased from 7% with TRAP alone to 18% when S195A was added to TRAP.

View larger version (27K): [in this window] [in a new window]   Figure 4. Phosphorylation and immunolocalization of ERKs after TRAP-induced stimulation of HUVECs in the presence of S195A. Cells were either unstimulated (A) or stimulated by 200 nmol/L S195A (B), 100 µmol/L TRAP (C), or S195A plus TRAP simultaneously (D) for 4 hours before fixation and examination as in Figure 3. The corresponding Western blots obtained with the anti–phospho-ERK antibody as in Figure 2 are shown at the bottom. Bar=30 µm.

We next prevented thrombin binding to TM with the monoclonal antibody 3E2 that we previously described to increase thrombin-induced DNA synthesis.⁹ Compared with control (Figure 5A), anti-TM by itself induced a slight increase of ERK phosphorylation (Figure 5B), as did, however, an irrelevant antibody (Figure 5C). After 4 hours of stimulation by thrombin, the amount of pERKs in the nucleus (Figure 5D) was decreased in the presence of the anti-TM (Figure 5E), suggesting that it accelerated the dephosphorylation. Moreover, in the presence of anti-TM, in 30% of the cells the pERKs remained at the edge of the nucleus membrane (red annulus around the blue nucleus) within the cytoplasm (Figure 5E) compared with <3% in the absence of the antibody. Thus, the number of thrombin-stimulated cells exhibiting a high level of pERKs in their nucleus was significantly reduced from 27% to 14% in the presence of the anti-TM antibody (P=0.02). These results suggest that thrombin binding to TM contributes to the maintenance of pERKs and nuclear retention.

View larger version (28K): [in this window] [in a new window]   Figure 5. Phosphorylation and immunolocalization of ERK1 and ERK2 after thrombin-induced stimulation of HUVECs in the presence of an anti-TM antibody. Cells were either unstimulated (A through C) or stimulated by 10 nmol/L thrombin alone (D) or 10 nmol/L thrombin in the presence of 50 µg/mL anti-TM antibody 3E2 (E) for 4 hours before fixation and examination as in Figure 3. Unstimulated cells were incubated with an irrelevant antibody (B) or the anti-TM alone (C) and stained as in panel A. The corresponding Western blots obtained with the anti–phospho-ERK antibody as in Figure 2 are shown at the bottom. Bar=30 µm.

	Discussion

Top Abstract Introduction Materials and Methods Results Discussion References

 
The activation of ERKs is an important step in cell stimulus–response coupling, and their localization is determinant of their function. In the present study, we found that after stimulation of HUVECs by thrombin or TRAP, ERK1 and ERK2 phosphorylation duration and nuclear retention were inversely correlated to the DNA synthesis. TRAP, a strong mitogen for HUVECs, induced a short-lasting phosphorylation and nuclear retention of pERKs; thrombin, which induced a lower DNA synthesis than did TRAP, induced a long-lasting phosphorylation and nuclear retention of pERKs. These results additionally demonstrate the regulatory role of TM in thrombin-induced PAR1 activation: TM, known to reduce HUVEC proliferation in response to thrombin, extended pERK nuclear retention.^{7 9}

The activation of ERKs is dependent on a dual-specificity MAPK kinase, MEK.^{14 23} ERKs are phosphorylated on a TXY motif, both on threonine and tyrosine residues, and these phosphorylations are essential for activity.¹¹ The stimulation of HUVECs by thrombin and TRAP led to DNA synthesis through activation of the ERK pathway. First, proliferation of DNA synthesis was strongly and dose-dependently inhibited by PD98059. PD98059 is a semiselective inhibitor of MEK1 and MEK2 and thus inhibits the phosphorylation of MEK substrates, the MAPKs. Second, thrombin and TRAP induced the phosphorylation of 2 members of the MAPK family, p44^ERK1 and p42^ERK2. This phosphorylation was rapid and reached a plateau of approximately similar amplitude with thrombin and TRAP. After longer times (>2 hours), phosphorylation decreased, and the dephosphorylation was more rapid with TRAP than with thrombin. The duration of ERK phosphorylation and activation is critical for the cell signaling decision: cells use transient or sustained activation of ERKs, depending on the response.¹⁴ In the present study, we showed that in HUVECs, activation of PAR1 induced transient ERK phosphorylation and led to DNA synthesis.

The MAPK pathway that ultimately leads to cell proliferation or differentiation provides a mechanism that transmits the information to the nucleus.²⁴ The nuclear translocation step concerns activated pERKs.¹³ Once in the nucleus, ERKs phosphorylate and activate transcriptional factor.^{25 26} In HUVECs, using immunocytochemical analysis, we showed that pERKs were translocated in the nucleus after stimulation by TRAP and by thrombin. However, the retention time in the nucleus was different with the two agonists. After 4 hours of stimulation, pERKs were still present in the nucleus of thrombin-activated cells, whereas they were barely detectable in TRAP-stimulated cells. Thus, pERK retention in the nucleus correlated with the protein phosphorylation state.

Thrombin and TRAP may activate different PAR receptors. At least 3 PAR receptors have already been described on endothelial cells (PAR1, PAR2, and PAR3), of which PAR1 and PAR2 are involved in endothelial cell proliferation.^{27 28} Moreover, TRAP is able to activate PAR1 even after thrombin cleavage. On the other hand, HUVEC proliferation induced by thrombin is downregulated by thrombin binding to TM.⁹ Overexpression of TM on smooth muscle cell surface decreases the TRAP-induced proliferation.⁷ Surface TM expression downregulates melanoma cell proliferation independently of its thrombin cofactor activity.¹⁰ In the strategy to specifically isolate the effect of thrombin binding to TM, we used a thrombin analogue devoid of any catalytic activity, S195A, and a specific monoclonal anti-TM antibody, 3E2. Hence, using these 2 different tools, we demonstrated that TM regulated the pERK nuclear retention. First, in the presence of anti-TM antibody that inhibits thrombin binding to TM, pERK nuclear retention was reduced. Second, the addition of an inactive thrombin mutant that binds to TM together with TRAP prolonged pERK nuclear retention. These data suggest that thrombin binding to TM triggers a signal that enhances pERK nuclear retention. Thus, in addition to its role of cofactor to activate protein C, TM seems to act as a new cell receptor for thrombin.

The mechanism required for the nuclear translocation has been elucidated for ERK2: phosphorylation creates charge-charge interactions that result in ERK dimerization, and dimers are actively imported into the nucleus.¹³ The transient phosphorylation of ERKs in stimulated HUVECs suggests that the proteins are under the control of phosphatases. Many cytosolic and nuclear MAPK phosphatases dephosphorylate ERKs in their respective cell compartments.^{23 29} Similar phosphatase-controlled phosphorylation regulation could occur in HUVECs. The results described above also suggest that TM could govern nuclear pERK retention. Thrombomodulin could trigger a signal to inhibit a nuclear MAPK phosphatase (MKP), such as MKP1 (Figure 6). MKP1 is implicated in the initiation of the cell cycle and activated by pERKs via a feedback control.³⁰ It is not unlikely that TM controls MKP1 activation by pERKs.

View larger version (26K): [in this window] [in a new window]   Figure 6. Proposed model for the regulation of ERK phosphorylation by TM. ERK1 and ERK2 are phosphorylated by MEK1, dimerized, and translocated into the nucleus, where they are visualized in red. Activation of ERKs is a reversible process because of phosphatases, among which MKP1 is in the nucleus.30 The putative inhibitory role of TM on MKP1-induced ERK dephosphorylation is addressed.

Thrombin-induced endothelial cell response is of special importance during ischemia consecutive to arterial embolic disorders. The latter corresponds to pathological situations in which the endothelium integrity is relatively preserved, in contrast to local thrombosis occurring at the site of an atherosclerotic plaque rupture. The thrombin generated by an embolic clot comes into contact with endothelial cells and enhances edema, cell proliferation, and fibrosis.¹ The involvement of TM, on the one hand, and pERK signaling, on the other hand, has been emphasized in arterial thrombotic disorders. ERK activation leads to deleterious effects during focal brain or myocardial ischemia.^{31 32 33} Although myocardial infarction is most frequently the consequence of local thrombosis, ischemic strokes more frequently result from embolic disorders.³⁴ TM expression has been demonstrated in brain vessels, because TM mRNA expression is present in the blood-brain barrier³⁵ and protein C is activated in jugular vein blood during carotid artery occlusion in humans.³⁶ The endothelial TM expression in brain is constitutively downregulated by astrocytes and acutely downregulated by pathogenic mediators of ischemic stroke, such as interleukin-1ß and tumor necrosis factor-.³⁵ Interestingly, astrocyte-induced downregulation of TM endothelial expression occurs through transforming growth factor-ß secretion,³⁷ known to enhance endothelial cell proliferation.³⁸ Overall, that TM expression and cell proliferation are inversely related fits with our results, showing a control of DNA synthesis by TM.

In conclusion, we show that TM controls the thrombin-induced ERK pathway in endothelial cells. Thus, TM, which plays a key role in the regulation of blood coagulation, could also be critically involved in the endothelial response to thrombosis. The latter would be of important clinical relevance in acute arterial ischemia, as recently suggested by epidemiological studies on myocardial infarction.^{39 40} It is thus worthwhile to study the implication of TM in ischemic stroke.

	Acknowledgments

 
This work was supported by Association pour la Recherche sur le Cancer (grant 9545 to F.R.). J.-M.O. was a recipient of a grant from the Fondation pour la Recherche Médicale. We are indebted to Dr B. Le Bonniec for providing us with the mutated thrombin S195A and to Drs G. Keryer and J. Badet for their helpful advice for the immunofluorescence study.

	Footnotes

 
Original received October 6, 2000; revision received January 18, 2001; accepted February 9, 2001.

	References

Top Abstract Introduction Materials and Methods Results Discussion References

 
1. Grand RJ, Turnell AS, Grabham PW. Cellular consequences of thrombin-receptor activation. Biochem J. 1996;313:353–368.

2. Coughlin SR. How the protease thrombin talks to cells. Proc Natl Acad Sci U S A. 1999;96:11023–11027.

3. Wood MJ, Sampoli BB, Komives EA. Solution structure of the smallest cofactoactive fragment of thrombomodulin. Nat Struct Biol. 2000;7:200–204.

4. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64:1057–1068.

5. Wheeler-Jones C, Abu-Ghazaleh R, Cospedal R, Houliston RA, Martin J, Zachary I. Vascular endothelial growth factor stimulates prostacyclin production and activation of cytosolic phospholipase A2 in endothelial cells via p42/p44 mitogen-activated protein kinase. FEBS Lett. 1997;420:28–32.

6. Hammes SR, Coughlin SR. Protease-activated receptor-1 can mediate responses to SFLLRN in thrombin-desensitized cells: evidence for a novel mechanism for preventing or terminating signaling by PAR1’s tethered ligand. Biochemistry. 1999;38:2486–2493.

7. Grinnell BW, Berg DT. Surface thrombomodulin modulates thrombin receptor responses on vascular smooth muscle cells. Am J Physiol. 1996;270:H603–H609.

8. Amiral J, Adam M, Mimilla F, Larrivaz I, Chambrette B, Boffa MC. Design and validation of a new immunoassay for soluble forms of thrombomodulin and studies on plasma. Hybridoma. 1994;13:205–213.

9. Lafay M, Laguna R, Le Bonniec BF, Lasne D, Aiach M, Rendu F. Thrombomodulin modulates the mitogenic response to thrombin of human umbilical vein endothelial cells. Thromb Haemost. 1998;79:848–852.

10. Zhang Y, Weiler-Guettler H, Chen J, Wilhelm O, Deng Y, Qiu F, Nakagawa K, Klevesath M, Wilhelm S, Bohrer H, Nakagawa M, Graeff H, Martin E, Stern DM, Rosenberg RD, Ziegler R, Nawroth PP. Thrombomodulin modulates growth of tumor cells independent of its anticoagulant activity. J Clin Invest. 1998;101:1301–1309.

11. Anderson NG, Maller JL, Tonks NK, Sturgill TW. Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase. Nature. 1990;343:651–653.

12. Canagarajah BJ, Khokhlatchev A, Cobb MH, Goldsmith EJ. Activation mechanism of the MAP kinase ERK2 by dual phosphorylation. Cell. 1997;90:859–869.

13. Khokhlatchev AV, Canagarajah B, Wilsbacher J, Robinson M, Atkinson M, Goldsmith E, Cobb MH. Phosphorylation of the MAP kinase ERK2 promotes its homodimerization and nuclear translocation. Cell. 1998;93:605–615.

14. Marshall CJ. Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell. 1995;80:179–185.

15. Van Obberghen-Schilling E, Vouret-Craviari V, Chen YH, Grall D, Chambard JC, Pouyssegur J. Thrombin and its receptor in growth control. Ann N Y Acad Sci. 1995;766:431–441.

16. Lin LL, Wartmann M, Lin AY, Knopf JL, Seth A, Davis RJ. cPLA2 is phosphorylated and activated by MAP kinase. Cell. 1993;72:269–278.

17. Wheeler-Jones CP, May MJ, Houliston RA, Pearson JD. Inhibition of MAP kinase kinase (MEK) blocks endothelial PGI₂ release but has no effect on von Willebrand factor secretion or E-selectin expression. FEBS Lett. 1996;388:180–184.

18. Le Bonniec BF, Esmon CT. Glu-192 to Gln substitution in thrombin mimics the catalytic switch induced by thrombomodulin. Proc Natl Acad Sci U S A. 1991;88:7371–7375.

19. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins: identification by morphologic and immunologic criteria. J Clin Invest. 1973;52:2745–2756.

20. Dimon-Gadal S, Raynaud F, Evain-Brion D, Keryer G. MAP kinase abnormalities in hyperproliferative cultured fibroblasts from psoriatic skin. J Invest Dermatol. 1998;110:872–879.

21. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A. 1995;92:7686–7689.

22. Dupuy E, Bikfalvi A, Rendu F, Toledano SL, Tobelem G. Thrombin mitogenic responses and protein phosphorylation are different in cultured human endothelial cells derived from large and microvessels. Exp Cell Res. 1989;185:363–372.

23. Hunter T. Protein kinases and phosphatases: the yin and yang of protein phosphorylation and signaling. Cell. 1995;80:225–236.

24. Brunet A, Roux D, Lenormand P, Dowd S, Keyse S, Pouyssegur J. Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J. 1999;18:664–674.

25. Janknecht R, Hunter T. Nuclear fusion of signaling pathways. Science. 1999;284:443–444.

26. Hill CS, Treisman R. Transcriptional regulation by extracellular signals: mechanisms and specificity. Cell. 1995;80:199–211.

27. Hwa JJ, Ghibaudi L, Williams P, Chintala M, Zhang R, Chatterjee M, Sybertz E. Evidence for the presence of a proteinase-activated receptor distinct from the thrombin receptor in vascular endothelial cells. Circ Res. 1996;78:581–588.

28. Mirza H, Yatsula V, Bahou WF. The proteinase activated receptor-2 (PAR-2) mediates mitogenic responses in human vascular endothelial cells. J Clin Invest. 1996;97:1705–1714.

29. Camps M, Nichols A, Arkinstall S. Dual specificity phosphatases: a gene family for control of MAP kinase function. FASEB J. 2000;14:6–16.

30. Brondello JM, Pouyssegur J, McKenzie FR. Reduced MAP kinase phosphatase-1 degradation after p42/p44 MAPK-dependent phosphorylation. Science. 1999;286:2514–2517.

31. Alessandrini A, Namura S, Moskowitz MA, Bonventre JV. MEK1 protein kinase inhibition protects against damage resulting from focal cerebral ischemia. Proc Natl Acad Sci U S A. 1999;96:12866–12869.

32. Omura T, Yoshiyama M, Shimada T, Shimizu N, Kim S, Iwao H, Takeuchi K, Yoshikawa J. Activation of mitogen-activated protein kinases in in vivo ischemia/reperfused myocardium in rats. J Mol Cell Cardiol. 1999;31:1269–1279.

33. Shimizu N, Yoshiyama M, Omura T, Hanatani A, Kim S, Takeuchi K, Iwao H, Yoshikawa J. Activation of mitogen-activated protein kinases and activator protein-1 in myocardial infarction in rats. Cardiovasc Res. 1998;38:116–124.

34. Babikian VL, Caplan LR. Brain embolism is a dynamic process with variable characteristics. Neurology. 2000;54:797–801.

35. Tran ND, Wong VL, Schreiber SS, Bready JV, Fisher M. Regulation of brain capillary endothelial thrombomodulin mRNA expression. Stroke. 1996;27:2304–2310.

36. Macko RF, Killewich LA, Fernandez JA, Cox DK, Gruber A, Griffin JH. Brain-specific protein C activation during carotid artery occlusion in humans. Stroke. 1999;30:542–545.

37. Tran ND, Correale J, Schreiber SS, Fisher M. Transforming growth factor-ß mediates astrocyte-specific regulation of brain endothelial anticoagulant factors. Stroke. 1999;30:1671–1678.

38. Iruela-Arispe ML, Sage EH. Endothelial cells exhibiting angiogenesis in vitro proliferate in response to TGF-ß1. J Cell Biochem. 1993;52:414–430.

39. Esmon CT. Defects in natural anticoagulant pathways as potential risk factors for myocardial infarction. Circulation. 1997;96:9–11.

40. Ireland H, Kunz G, Kyriakoulis K, Stubbs PJ, Lane DA. Thrombomodulin gene mutations associated with myocardial infarction. Circulation. 1997;96:15–18.

This article has been cited by other articles:

				A. A. Sharfuddin, R. M. Sandoval, D. T. Berg, G. E. McDougal, S. B. Campos, C. L. Phillips, B. E. Jones, A. Gupta, B. W. Grinnell, and B. A. Molitoris Soluble Thrombomodulin Protects Ischemic Kidneys J. Am. Soc. Nephrol., March 1, 2009; 20(3): 524 - 534. [Abstract] [Full Text] [PDF]

				N. Ozgen, M. Obreztchikova, J. Guo, H. Elouardighi, G. W. Dorn II, B. A. Wilson, and S. F. Steinberg Protein Kinase D Links Gq-coupled Receptors to cAMP Response Element-binding Protein (CREB)-Ser133 Phosphorylation in the Heart J. Biol. Chem., June 20, 2008; 283(25): 17009 - 17019. [Abstract] [Full Text] [PDF]

				P. Zania, M. Papaconstantinou, C. S. Flordellis, M. E. Maragoudakis, and N. E. Tsopanoglou Thrombin mediates mitogenesis and survival of human endothelial cells through distinct mechanisms Am J Physiol Cell Physiol, May 1, 2008; 294(5): C1215 - C1226. [Abstract] [Full Text] [PDF]

				M. Fujiwara, M. Ghazizadeh, and O. Kawanami Potential role of the Slit/Robo signal pathway in angiogenesis Vascular Medicine, May 1, 2006; 11(2): 69 - 74. [Abstract] [PDF]

				E. A. Lidington, R. Steinberg, A. R. Kinderlerer, R. C. Landis, M. Ohba, A. Samarel, D. O. Haskard, and J. C. Mason A role for proteinase-activated receptor 2 and PKC-{epsilon} in thrombin-mediated induction of decay-accelerating factor on human endothelial cells Am J Physiol Cell Physiol, December 1, 2005; 289(6): C1437 - C1447. [Abstract] [Full Text] [PDF]

				D. M. Smadja, I. Bieche, G. Uzan, H. Bompais, L. Muller, C. Boisson-Vidal, M. Vidaud, M. Aiach, and P. Gaussem PAR-1 Activation on Human Late Endothelial Progenitor Cells Enhances Angiogenesis In Vitro With Upregulation of the SDF-1/CXCR4 System Arterioscler Thromb Vasc Biol, November 1, 2005; 25(11): 2321 - 2327. [Abstract] [Full Text] [PDF]

				M. David-Dufilho, E. M.-V. Brussel, G. Topal, L. Walch, A. Brunet, and F. Rendu Endothelial Thrombomodulin Induces Ca2+ Signals and Nitric Oxide Synthesis through Epidermal Growth Factor Receptor Kinase and Calmodulin Kinase II J. Biol. Chem., October 28, 2005; 280(43): 35999 - 36006. [Abstract] [Full Text] [PDF]

				K. Rabausch, E. Bretschneider, M. Sarbia, J. Meyer-Kirchrath, P. Censarek, R. Pape, J. W. Fischer, K. Schror, and A.-A. Weber Regulation of Thrombomodulin Expression in Human Vascular Smooth Muscle Cells by COX-2-Derived Prostaglandins Circ. Res., January 7, 2005; 96(1): e1 - e6. [Abstract] [Full Text] [PDF]

				J.-M. Olivot, J. Labreuche, M. Aiach, P. Amarenco, and for the GENIC Investigators Soluble Thrombomodulin and Brain Infarction: Case-Control and Prospective Study Stroke, August 1, 2004; 35(8): 1946 - 1951. [Abstract] [Full Text] [PDF]

				T. Minami, A. Sugiyama, S.-Q. Wu, R. Abid, T. Kodama, and W. C. Aird Thrombin and Phenotypic Modulation of the Endothelium Arterioscler Thromb Vasc Biol, January 1, 2004; 24(1): 41 - 53. [Abstract] [Full Text] [PDF]

				S.-Q. Wu, T. Minami, D. J. Donovan, and W. C. Aird The proximal serum response element in the Egr-1 promoter mediates response to thrombin in primary human endothelial cells Blood, December 15, 2002; 100(13): 4454 - 4461. [Abstract] [Full Text] [PDF]

				R. Opavsky, P. Haviernik, D. Jurkovicova, M. T. Garin, N. G. Copeland, D. J. Gilbert, N. A. Jenkins, J. Bies, S. Garfield, S. Pastorekova, et al. Molecular Characterization of the Mouse Tem1/endosialin Gene Regulated by Cell Density in Vitro and Expressed in Normal Tissues in Vivo J. Biol. Chem., October 12, 2001; 276(42): 38795 - 38807. [Abstract] [Full Text] [PDF]

				J. E. Freedman Thrombin, Thrombomodulin, and Extracellular Signal-Regulated Kinases Regulating Cellular Proliferation Circ. Res., April 13, 2001; 88(7): 651 - 653. [Full Text] [PDF]

This Article Abstract Full Text (PDF) All Versions of this Article: 88/7/681    most recent hh0701.088769v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Olivot, J.-M. Articles by Rendu, F. Search for Related Content PubMed PubMed Citation Articles by Olivot, J.-M. Articles by Rendu, F. Related Collections Cell signalling/signal transduction Endothelium/vascular type/nitric oxide